New pill holds promise for fewer side effects in treating leukemia

January 7, 2013 by Bob Yirka, Medical Xpress report
Discovery of ABT-199. Credit: Nature Medicine (2013) doi:10.1038/nm.3048

(Medical Xpress)—An international team of researchers has developed a new anti-cancer drug that holds promise as a therapy that fights cancer while causing fewer side effects than current medicines. The work done by the group – mainly in the US and Australia – and the results they've achieved are described in an article published by the team in Nature Medicine.

The pill, known as ABT-199, works by attacking a key BCL-2 protein that use to ward off the beneficial effects of traditional chemotherapy. BCL-2 proteins, known as pro-survival proteins, inhibit the therapeutic effects of chemotherapy which lead to a requirement for large doses and resultant negative side effects such as nausea and hair loss. In this new study, during trials in a medical care facility in Melbourne, Australia, a single ABT-199 pill was found to "dramatically" reduce the number of in the blood after just an eight hour period while causing few side effects.

BCL-2 (B-cell lymphoma 2) is one of the originally discovered members of the BCL-2 group of cell-death regulator proteins and is evident in the BCL2 gene. It has been seen in a number of cancers and has also been linked to some and . When present in cancer, it is believed to work as an inhibitor, providing resistance against cancer treating drugs. The goal of this new work was to develop a drug that would eliminate or reduce the presence of the protein in which would allow chemotherapy to do its job.

One of the main hurdles the team had to overcome was to find a substance that would inhibit the growth of BCL-2 without disturbing the growth of BCL-XL – a protein necessary for platelet development. Because the two are so similar, prior efforts to curb the deleterious protein, generally resulted in harming the helpful one. As trials have continued, it appears the team has overcome this problem as the team reports there have thus far been no adverse impact on BCL-XL levels as tumors have been reduced in patients.

The team came up with the formula for the new pill by studying existing anti-BCL drugs – gradually weeding out the ones that harmed BCL-XL. They report that trials with three patients show that the new pill demonstrates a promising new therapy for treating several types of cancers while simultaneously reducing negative side effects.

Explore further: New agents show promise for treating aggressive breast cancers

More information: ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets, Nature Medicine (2013) doi:10.1038/nm.3048

Abstract
Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are key regulators of the apoptotic process. This family comprises proapoptotic and prosurvival proteins, and shifting the balance toward the latter is an established mechanism whereby cancer cells evade apoptosis. The therapeutic potential of directly inhibiting prosurvival proteins was unveiled with the development of navitoclax, a selective inhibitor of both BCL-2 and BCL-2–like 1 (BCL-XL), which has shown clinical efficacy in some BCL-2–dependent hematological cancers. However, concomitant on-target thrombocytopenia caused by BCL-XL inhibition limits the efficacy achievable with this agent. Here we report the re-engineering of navitoclax to create a highly potent, orally bioavailable and BCL-2–selective inhibitor, ABT-199. This compound inhibits the growth of BCL-2–dependent tumors in vivo and spares human platelets. A single dose of ABT-199 in three patients with refractory chronic lymphocytic leukemia resulted in tumor lysis within 24 h. These data indicate that selective pharmacological inhibition of BCL-2 shows promise for the treatment of BCL-2–dependent hematological cancers.

Related Stories

New agents show promise for treating aggressive breast cancers

July 18, 2011
Some of the most aggressive forms of breast cancer are more vulnerable to chemotherapy when it is combined with a new class of anti-cancer agent, researchers from the Walter and Eliza Hall Institute have shown.

Marked for destruction: Newly developed compound triggers cancer cell death

May 24, 2012
The BCL-2 protein family plays a large role in determining whether cancer cells survive in response to therapy or undergo a form of cell death known as apoptosis. Cells are pressured toward apoptosis by expression of pro-apoptotic ...

Recommended for you

Presurgical targeted therapy delays relapse of high-risk stage 3 melanoma

January 17, 2018
A pair of targeted therapies given before and after surgery for melanoma produced at least a six-fold increase in time to progression compared to standard-of-care surgery for patients with stage 3 disease, researchers at ...

Dulling cancer therapy's double-edged sword

January 17, 2018
Researchers have discovered that killing cancer cells can actually have the unintended effect of fueling the proliferation of residual, living cancer cells, ultimately leading to aggressive tumor progression.

Researchers develop swallowable test to detect pre-cancerous Barrett's esophagus

January 17, 2018
Investigators at Case Western Reserve University School of Medicine and University Hospitals Cleveland Medical Center have developed a simple, swallowable test for early detection of Barrett's esophagus that offers promise ...

Scientists zoom in to watch DNA code being read

January 17, 2018
Scientists have unveiled incredible images of how the DNA code is read and interpreted—revealing new detail about one of the fundamental processes of life.

T-cells engineered to outsmart tumors induce clinical responses in relapsed Hodgkin lymphoma

January 16, 2018
WASHINGTON-(Jan. 16, 2018)-Tumors have come up with ingenious strategies that enable them to evade detection and destruction by the immune system. So, a research team that includes Children's National Health System clinician-researchers ...

Researchers identify new treatment target for melanoma

January 16, 2018
Researchers in the Perelman School of Medicine at the University of Pennsylvania have identified a new therapeutic target for the treatment of melanoma. For decades, research has associated female sex and a history of previous ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.